RNA Targeting Small Molecules Therapeutics Market Size Projected To Reach $22.36 Billion By 2034 With A Cagr Of 29.8%

The RNA Targeting Small Molecules Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the RNA Targeting Small Molecules Therapeutics Market?
The market size of RNA targeting small molecules therapeutics has seen a remarkable growth in the past few years. It is projected to expand from $6.1 billion in 2024 to $7.87 billion in 2025, having a compound annual growth rate (CAGR) of 28.9%. Factors contributing to this notable growth in the historical period include advancements in drug discovery and development, increasing incidence of RNA-associated diseases, support from government and private sectors, interest from the pharmaceutical industry, alongside the success stories of RNA therapeutics.

The market for small molecule therapeutics that target RNA is projected to experience substantial growth in the next several years, ultimately reaching a value of $22.36 billion by 2029, with a compound annual growth rate (CAGR) of 29.8%. This predicted growth in the forecast period is largely due to factors such as precision and personalized therapies, an increase in the identification of RNA biomarkers, an expanded RNA target spectrum, more funding and investments, and applications in treating rare diseases. Main trends for the forecast period consist of improvements in screening technologies, the dominance of antisense oligonucleotides, small molecule RNA binders, the use of RNA therapeutics in treating neurological disorders, and gene editing using the crispr-cas9 method.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12253

What Are the Different RNA Targeting Small Molecules Therapeutics Market Segments?
The RNA targeting small molecules therapeutics market covered in this report is segmented -

1) By Offering: mRNA (Messenger Ribonucleic Acid) Translation Modulators, RNA (Ribonucleic Acid) Splicing Modification, Direct RNA (Ribonucleic Acid) Targeting, Other Offerings
2) By Therapeutic Indication: Lung Fibrosis, Cancer, Neurodegenerative Diseases, Autoimmune, Inflammatory, Other Therapeutic Indications
3) By Application: Drug Discovery, Oncology Research, Disease Identification
4) By End User: Hospitals, Research Laboratories, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:
1) By mRNA (Messenger Ribonucleic Acid) Translation Modulators: Small Molecule Inhibitors, Enhancers Of Translation
2) By RNA (Ribonucleic Acid) Splicing Modification: Splicing Modulators, Antisense Oligonucleotides
3) By Direct RNA (Ribonucleic Acid) Targeting: RNA-Binding Small Molecules, RNA Aptamers
4) By Other Offerings: RNA Interference (RNAi) Therapeutics, Small Molecule Activators Of RNA Stability

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12253&type=smp

What Are the Primary Drivers Shaping the RNA Targeting Small Molecules Therapeutics Market?
The surge in cancer incidences is slated to fuel the expansion of the RNA-targeting small molecule therapeutics market in the future. Cancer is a broad term describing ailments that can occur in almost any organ or tissue when abnormal cells begin to grow out of control, breach their normal limits, and either invade other organs or infiltrate adjacent parts of the body. RNA-targeting small molecules, which are designed and studied to selectively target RNA molecules related to cancer, are used in cancer treatment. For example, the American Cancer Society, a health organization based in the US, released research in January 2022 indicating that an estimated 609,360 cancer deaths and 1.9 million new case of cancer are expected in the US in 2022, which translates to around 1,670 deaths per day. Thus, the escalating prevalence of cancer is contributing to the progress of the RNA-targeting small molecule therapeutics market.

Which Companies Are Leading in the RNA Targeting Small Molecules Therapeutics Market?
Major companies operating in the RNA targeting small molecules therapeutics market include F. Hoffmann-La Roche Ltd., Bayer AG, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Janssen Pharmaceuticals, Vertex Pharmaceuticals, Servier laboratories, Genentech Inc., PTC Therapeutics Inc., Arrakis Therapeutics, Anima Biotech Inc., Skyhawk Therapeutics Inc., Remix Therapeutics, Abivax SA, 858 Therapeutics, Eloxx Pharmaceuticals Inc., STORM Therapeutics Ltd., Accent Therapeutics Inc., eFFECTOR Therapeutics Inc., EPICS Therapeutics, Expansion Therapeutics Inc., Inspirna Inc., MiNA Therapeutics Ltd., Ribometrix Inc., AC Immune SA, Redona Therapeutics

What Are the Major Trends Shaping the RNA Targeting Small Molecules Therapeutics Market?
The emerging trend of strategic collaborations is significantly influencing the RNA-targeting small molecule therapeutics market. Several leading companies in this market are establishing partnerships as part of their strategy to co-develop cutting-edge products. To illustrate, in June 2022, Otsuka Pharmaceutical Co. Ltd., a leading pharmaceutical manufacturer from Japan, partnered with xFOREST Therapeutics Co. Ltd., a Japanese firm specializing in the development of drug discovery platforms. The main aim of this collaboration is for xFOREST to provide Otsuka with its proprietary Forest technology, which will be crucial in driving forward research on small-molecule drug discovery, specifically targeting RNA structures. Additionally, in April 2024, Ipsen, a biopharmaceutical company based in France, joined forces with Skyhawk Therapeutics, a US-based clinical-stage biotech firm. Through this partnership, Ipsen plans to develop small molecule drugs that target RNA, aiming to treat rare neurological diseases, simultaneously leveraging various data sets to discover and develop small molecules that can modulate RNA.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecules-therapeutics-global-market-report

What Are the Top Revenue-Generating Geographies in the RNA Targeting Small Molecules Therapeutics Market?
North America was the largest region in the RNA targeting small molecules therapeutics market in 2024. The regions covered in the RNA targeting small molecules therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the RNA Targeting Small Molecules Therapeutics Market?
2. What is the CAGR expected in the RNA Targeting Small Molecules Therapeutics Market?
3. What Are the Key Innovations Transforming the RNA Targeting Small Molecules Therapeutics Industry?
4. Which Region Is Leading the RNA Targeting Small Molecules Therapeutics Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.